🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🧬 Presented at #EAS2025 | GAELp(a) Registry – Argentina 🇦🇷 Our study evaluated the concordance of three widely used Lp(a) unit conversion methods (nmol/L to mg/dL) in >1,000 individuals from the GAELp(a) Registry. 📊 Methods analyzed: 1️⃣ Fixed factor (1 mg/dL = 2.42 nmol/L) 2️⃣

🧬 Are very low Lipoprotein(a) levels a hidden metabolic risk? In our latest review in Current Opinion in Lipidology, we explore the paradoxical relationship between Lp(a), insulin resistance, and type 2 diabetes. 🔎 Key insights: 1⃣Elevated Lp(a) increases cardiovascular risk

¿Qué sabemos realmente sobre Lp(a)? ¿Y qué nos queda por descubrir? Te invitamos a participar del 3° Ateneo Bibliográfico de la Sociedad Argentina de Lípidos: “Entre incertidumbres y evidencias: Desafío Lp(a)” 📅Lunes 19 de mayo – 20 h (ARG) Actividad virtual, gratuita y con

📍 LATAM in numbers: 🔹 20 countries 🔹 666 million people 🔹 Lp(a) testing is possible — but not accessible 💬 According to our recent survey, Lp(a) can be measured in daily clinical practice across LATAM, but access is limited and uneven due to inconsistent reimbursement. This

👉Curso European Atherosclerosis Society Dislipidemias Raras o poco frecuentes 🙌Imperdible actividad en español! 📆 11 Junio 16 hs. (ART) ☝️Actividad no arancelada 👨🏻‍⚕️🧑🏻‍⚕️Con la participación de un cuerpo docente de primer nivel Raul Santos Laura Schreier Rodrigo Alonso Karlezi juan Patricio

👉Lipid-lowering in diabetes: An update Comprehensive update on lipid management in diabetes. ☝️This review highlights the central role of apoB-containing lipoproteins and supports early combination therapy (statin + ezetimibe) to achieve LDL-C targets in high-risk patients.

👉¡No te lo pierdas! Este martes 27 de mayo a las 19:00 (hora COL) 21:00 (hora ARG) acompañanos en el webinar: ☝️“Más allá del Congreso: Highlights de EAS y EAS Latam en Dislipidemia” Organizado por la Sociedad Colombiana de Cardiología y Cirugía Cardiovascular. 🧑🏻‍⚕️Dra. Luz

☝️Not the first one…Enlecitide (MK 0616) reduces LDL-C by up to 60% jacc.org/doi/10.1016/j.…

Invitation from Professor Pablo Corral Join us for the upcoming EAS Advanced Course on Rare Lipid Disorders: Bridging Knowledge and Clinical Practice in LatAm 🗓️ Date: 11 June 2025 🕓 Time: 16:00 ART (Argentina Time) 🌐 This course will be delivered in Spanish 👨‍⚕️ Tailored for

🔴 Rumbo al XLII Congreso Nacional de Cardiología – Mendoza 2025 Tendré el privilegio de participar en este importante encuentro científico con dos presentaciones centradas en temas clave para la prevención cardiovascular: 🧬 Lipoproteína(a): ¿Qué aprendimos y qué queda por

📄 New publication in European Heart Journal Open: 🧬Using Mendelian randomization across >1 million individuals, Benn et al. report that genetically low LDL-C is associated with: 👉Reduced risk of bacterial infections (including pneumonia, sepsis, and diarrhoeal diseases)

📢 1 week to go – don’t miss out! Join Professor Pablo Corral and leading experts for the EAS Advanced Course on Rare Lipid Disorders: Bridging Knowledge and Clinical Practice in LatAm 🗓️ Date: 11 June 2025 🕓 Time: 16:00 ART 🌐 Language: Spanish ✅ Deep dive into genetics,

📢New EAS Consensus Statement – Systemic Metabolic Disorder as a Unified Clinical Entity. Published in European Heart Journal (2025) The European Atherosclerosis Society introduces a clinically actionable, pathophysiology-based 3-stage classificationof Systemic Metabolic Disorder (SMD) — a

☝️Atherosclerosis IS NOT an inflammatory disease 👉Tuberculosis is not an inflammatory disease. It’s an infectious disease 👉HIV is not an inflammatory disease. It’s an infectious disease 👉Rheumatoid arthritis is an inflammatory disease. 👉Systemic lupus erythematosus is an

Curso avanzado de dislipemias raras o poco frecuentes European Atherosclerosis Society Sociedad Argentina Lípidos (SAL) Pablo Corral MD 🗓️miercoles 11 de junio ✏️ us02web.zoom.us/webinar/regist…

Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia merck.com/news/merck-ann…